Targeting the Source of Painful Rash and Irritation
SponsorPfizer
IndicationAtopic Dermatitis
MaterialsPatient Outreach
Patient Education
Site Staff Materials
Referring Physician
Patient Retention
Pfizer was conducting a phase 3 clinical study for its once-daily Janus kinase 1- (JAK1) selective inhibitor, PF-04965842, to evaluate the safety and efficacy of the drug for the treatment of moderate to severe atopic dermatitis (AD). AD, also commonly referred to as atopic eczema, is inflammation of the skin characterized by redness, itching, papulation, and crusting. This is the first clinical study in Pfizer’s JAK1 Atopic Dermatitis Efficacy and safety (JADE) global development program.
PF-04965842 is an oral small-molecule drug that selectively inhibits JAK1. The inhibition of JAK1 controls multiple cytokines involved in pathophysiology of AD including interleukin (IL)-4, IL-13, IL-31 and interferon gamma.
PF-04965842 is an oral small-molecule drug that selectively inhibits JAK1. The inhibition of JAK1 controls multiple cytokines involved in pathophysiology of AD including interleukin (IL)-4, IL-13, IL-31 and interferon gamma.
